Semaglutide has mostly been discussed as a drug for weight loss and diabetes. But a new study suggests its effects may reach beyond the stomach, possibly into brain circuits involved in reward, impulse control, and the urge to reach for alcohol.
Researchers in Denmark tested semaglutide in 108 adults with obesity who were also seeking help for problematic drinking. The result was not a miracle injection for alcohol addiction. But it was something medicine cannot easily ignore. After six months, people in the semaglutide group had far fewer heavy drinking days than they had at the start of the study.
People on semaglutide drank heavily less often. The difference showed up clearly in the calendar
At the start of the study, participants had an average of 17 heavy drinking days over the previous 30 days. In other words, alcohol was not an occasional slip for them. It was taking up more than half the month.
After six months, the gap between the two groups became clear. People who received semaglutide once a week dropped to about 5 heavy drinking days per month. That means roughly 12 fewer heavy drinking days compared with the beginning of the trial.
The placebo group also improved, and that matters because all participants received psychological support as well. But the drop was smaller. Those on placebo went from about 17 to about 9 heavy drinking days per month. Semaglutide did not erase alcohol from patients’ lives, but the difference compared with placebo was large enough to catch researchers’ attention.
It was not only about fewer heavy drinking days. People also consumed much less alcohol overall
The effect was not limited to the number of days when people drank heavily. The total amount of alcohol they consumed over a month also changed.
At the start of the study, participants consumed an average of about 2,200 grams of alcohol, or roughly 157 U.S. standard drinks, over 30 days. After six months, the semaglutide group was down to about 650 grams. Put simply, their monthly alcohol intake fell to less than one-third of the original level.
The placebo group improved too, which is not surprising given that everyone in the trial also received psychological support. But the change was smaller. People on placebo dropped to about 1,175 grams of alcohol per month.
That is why the study matters. This was not just another observation from real-world data. It was a randomized controlled trial testing whether a GLP-1 receptor agonist could reduce alcohol consumption in patients with obesity and alcohol use disorder.
The results look promising even when compared with today’s alcohol-use-disorder medications
The findings become even more interesting when placed next to existing treatments for alcohol use disorder. The study authors note that approved medications can help, but their effects in clinical trials are often modest.
For example, a meta-analysis found no significant reduction in heavy drinking days with acamprosate compared with placebo. Extended-release naltrexone, another treatment option, has been associated with about 1.2 fewer heavy drinking days per month compared with placebo.
That makes semaglutide look like a very interesting candidate, but not a finished answer to alcohol addiction. In this trial, heavy drinking days in the semaglutide group fell from about 17 to about 5 per month. The placebo group also improved, from about 17 to about 9. So it would not be accurate to say the drug alone created a full 12-day advantage over treatment without an active drug.
Semaglutide may not affect only the stomach. The trail also leads to reward circuits in the brain
With semaglutide, it is tempting to say people drank less simply because they lost weight. But the story is probably not that straightforward.
The study authors point out that GLP-1 drugs do not act only in the digestive system. Their effects may also reach the brain, especially circuits linked to reward, impulses, and cravings for addictive substances. In plain terms, semaglutide may not only slow stomach emptying and reduce hunger. It may also change how the brain responds to alcohol as a “reward”.
The study also found that people taking semaglutide lost weight in a way comparable to patients with obesity in other semaglutide trials. Researchers also saw a link between weight loss and fewer heavy drinking days. But the data cannot prove what caused what.
Part of the effect may be connected to the fact that alcohol is calorie-dense. When someone stops regularly drinking large amounts of alcohol, they naturally consume less energy. But it is also possible that the drug reduced the urge to drink, and weight loss was partly a result of that behavioral change. Future studies will have to separate these possibilities more clearly.
Semaglutide did not work for everyone. Some people kept drinking even at the highest dose
Like most medications, semaglutide did not help every participant. Some people showed little response even at the highest dose of 2.4 mg once a week. That point matters because the results are promising, but they do not mean this is an injection that automatically switches off alcohol cravings in everyone.
The strongest effect appeared in people with the most severe alcohol use disorder. Among those with milder cases, the result was less convincing, although that may partly reflect the smaller number of participants in that subgroup. In other words, the study points in a promising direction, but it does not yet tell doctors exactly which patients are most likely to benefit.
The safety data also need to be read carefully. Digestive problems, especially nausea, appeared more often in this trial than is typically described in people with obesity taking semaglutide without alcohol use disorder. Interestingly, more digestive complaints were also reported in the placebo group.
That suggests the problem may not be only the drug itself. People with long-term problematic drinking may have a more sensitive gastrointestinal system in general, which could make them more likely to experience or report these symptoms. Most of the reported problems were temporary and mild to moderate, but the authors stress that semaglutide’s safety in people with alcohol use disorder still needs to be studied outside the tightly monitored setting of a clinical trial.
Semaglutide could expand alcohol treatment, but for now only in a narrow group of patients
The study has limits that cannot be ignored. This was not a large trial involving thousands of people, and it did not include all patients with problematic drinking. Participants had obesity, defined as a BMI above 30, and they were actively seeking treatment for alcohol use disorder.
Another major question remains open. Researchers do not yet know what happens after treatment stops. Whether the reduced urge to drink lasts, or whether alcohol use gradually returns after discontinuation, will require longer follow-up. Safety will also need to be tested in routine clinical practice, outside a setting where participants had regular visits and psychological support.
Still, this is not a result that can simply be pushed aside. Alcohol use disorder is one of the world’s major health problems, and the authors note that it is linked to about 5% of deaths worldwide each year. If GLP-1 drugs can help some patients reduce not only body weight but also heavy drinking, it could open a new direction in treatment.
